Novartis' trial investigator Régis Peffault de Latour of Saint-Louis Hospital presents the APPLY results at ASH on Dec. 13 in New Orleans (Photo: Assistant editor Kyle LaHucik for Endpoints News)
December 13, 2022 10:00 AM ESTUpdated 10:27 AM
R&D
Pharma

#ASH22: No­var­tis PNH drug tops As­traZeneca with what's de­scribed as 'prac­tice-chang­ing' po­ten­tial

Kyle LaHucik

Senior Reporter

NEW OR­LEANS — No­var­tis showed hema­tol­o­gists and in­dus­try in­sid­ers Tues­day morn­ing just how well ip­ta­co­pan beat As­traZeneca’s two stan­dard-of-care med­i­cines for a rare blood dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times